Warner Chilcott Must Face Loestrin Pay-For-Delay MDL

Law360, New York (August 21, 2017, 7:06 PM EDT) -- Warner Chilcott Co. LLC, Watson Pharmaceuticals Inc. and Lupin Pharmaceuticals Inc. must face multidistrict litigation accusing them of entering into illegal reverse-payment deals to keep a generic of the birth control medication Loestrin off the market, according to an opinion unsealed Monday in Rhode Island federal court.

Chief U.S. District Judge William E. Smith said the purchasers bringing the so-called pay-for-delay litigation had sufficiently pled their antitrust and fraud allegations in a 118-page order released to the parties on Aug. 8. The judge's only cut was to free Warner and Watson's parent companies, Allergan PLC and Actavis Inc., as there were...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!